文献速递细菌感染、耐药与抗菌药物

铜绿假单胞菌菌血症抗生素疗程:BALANCE试验事后亚组分析

Duration of Therapy for Pseudomonas aeruginosa Bacteremia-A Post Hoc Subgroup Analysis From the BALANCE Randomized Controlled Trial.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该研究为BALANCE随机对照试验的事后亚组分析,纳入157例铜绿假单胞菌菌血症患者,比较7天与14天抗生素治疗的90天死亡率。样本量有限,无法得出非劣效、获益或 harm 的结论。

要点

  • 7天与14天抗生素治疗铜绿假单胞菌菌血症的90天死亡率无显著差异。
  • 年龄与90天死亡率独立相关(OR 1.06,95%CI 1.02-1.09)。
  • 样本量有限,不能排除非劣效、获益或 harm 的可能性。

核心结论

  • 在铜绿假单胞菌菌血症患者中,7天与14天抗生素治疗的90天死亡率无显著差异。
  • 因样本量有限,无法得出非劣效、获益或 harm 的结论。

研究设计与样本

  • BALANCE随机对照试验的事后亚组分析,纳入157例铜绿假单胞菌菌血症患者。
  • 患者随机接受7天(74例)或14天(83例)抗生素治疗。

主要发现

  • 90天粗死亡率:7天组29.7%(22/74),14天组20.5%(17/83),风险差9.2(95%CI -4.8至23.2)。

临床怎么用

  • 对于铜绿假单胞菌菌血症,7天疗程可作为考虑选项,但需结合患者具体情况个体化决策。
  • 因证据不确定性,不应将7天疗程作为所有患者的强制性标准。

局限性

  • 事后亚组分析,样本量有限,统计效能不足。
  • 7天组男性及医院获得性感染比例更高,可能存在混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the clinical significance of Pseudomonas aeruginosa bacteremia, the optimal duration of antibiotic therapy is unclear. We aimed to explore the association of antibiotic duration on mortality in hospitalized patients with P aeruginosa bacteremia. METHODS: This study was a post hoc analysis of all patients with P aeruginosa bacteremia included in the Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) randomized controlled trial comparing 7 versus 14 days of antibiotic therapy for bacteremia. The primary outcome was 90-day mortality. Unadjusted risk differences (RDs) with 95% CIs for outcomes were calculated for patients randomized to 7 versus 14 days of treatment. Multivariable logistic regression was used to evaluate independent predictors of mortality. RESULTS: Among 157 patients with P aeruginosa bacteremia, 74 were randomized to 7 days of antibiotic treatment and 83 to 14 days. Patients in the 7-day group were more likely to be men and acquire infection in hospital. Crude mortality at 90 days in the intention-to-treat population was 22/74 (29.7%) in the 7-day group versus 17/83 (20.5%) in the 14-day group (RD: 9.2; 95% CI: -4.8 to 23.2). Age was associated with 90-day mortality (odds ratio [OR]: 1.06; 95% CI: 1.02-1.09), but randomization group (7 or 14 days) was not (OR: 1.47; 95% CI: .66-3.27). CONCLUSIONS: Among patients with P aeruginosa bacteremia included in an international trial testing duration of antibiotic treatment, no significant difference in mortality was demonstrated between 7 versus 14 days of antibiotic therapy; however, a limited sample size precludes a conclusion of noninferiority, benefit, or harm.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yahav D, Pinto R, Cook D, et al. Duration of Therapy for Pseudomonas aeruginosa Bacteremia-A Post Hoc Subgroup Analysis From the BALANCE Randomized Controlled Trial. Clin Infect Dis. 2026. PMID: 41774760. doi:10.1093/cid/ciag144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。